The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...
Shares of Bristol Myers Squibb Co. BMY slumped 0.55% to $57.68 Friday, on what proved to be an all-around poor trading ...
Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Bristol-Myers ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...
Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $56.56 which represents a slight increase of $0.50 or 0.89% from the prior close of $56.06. The stock opened at $56.07 and ...
Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...
According to Benzinga Pro, Bristol-Myers Squibb's peer group average for short interest as a percentage of float is 4.30%, ...
We recently compiled a list of the Long-Term Stock Portfolio: Best Stocks for 10 Years. In this article, we are going to take ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback